The latest price target for Bioage Labs (NASDAQ:BIOA) was reported by Jefferies on February 18, 2026. The analyst firm set a price target for $62.00 expecting BIOA to rise to within 12 months (a possible 202.29% upside). 8 analyst firms have reported ratings in the last year.

The latest analyst rating for Bioage Labs (NASDAQ:BIOA) was provided by Jefferies, and Bioage Labs upgraded their buy rating.

The last upgrade for Bioage Labs Inc happened on February 18, 2026 when Jefferies raised their price target to $62. Jefferies previously had a hold for Bioage Labs Inc.

The last downgrade for Bioage Labs Inc happened on December 9, 2024 when Citigroup changed their price target from $45 to $7 for Bioage Labs Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Bioage Labs, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Bioage Labs was filed on February 18, 2026 so you should expect the next rating to be made available sometime around February 18, 2027.

While ratings are subjective and will change, the latest Bioage Labs (BIOA) rating was a upgraded with a price target of $9.00 to $62.00. The current price Bioage Labs (BIOA) is trading at is $20.51, which is within the analyst’s predicted range.